ArticlePloS one2019
Leveraging the electronic health record to eliminate hepatitis C: Screening in a large integrated healthcare system.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.The Lancet. Global health · 2021Pooled it
- Precision public-health intervention for care coordination: a real-world study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2023Trial
- Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.Open forum infectious diseases · 2026Article
- Hepatitis C Surveillance in the United States: Past, Present, and Future.Public health reports (Washington, D.C. : 1974) · 2025Review
- Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024Article
- Screening for Hepatitis C Among Community Health Center Patients by Ethnicity and Language Preference.AJPM focus · 2023Article
- Engaging Physicians and Systems to Improve Hepatitis C Virus Testing in Baby Boomers.Healthcare (Basel, Switzerland) · 2023Article
- HCV universal EHR prompt successfully increases screening, highlights potential disparities.PloS one · 2023Article
- An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population.Microbiology spectrum · 2022Article
- Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review.JMIR medical informatics · 2022Article
- Prevalence, treatment, and control of severe hyperlipidemia.American journal of preventive cardiology · 2020Article
- Hepatitis C Testing and Liver Fibrosis Predictors in the Birth Cohort of a Primary Care Practice.Mayo Clinic proceedings. Innovations, quality & outcomes · 2020Article
- Cascade of Care for Alaska Native People With Chronic Hepatitis C Virus Infection: Statewide Program With High Linkage to Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Screening for hepatitis C as part of an opioid stewardship quality improvement initiative: Identifying infected patients and analyzing linkage to care.Clinical liver diseaseArticle
- Oral Prescription Opioids as a High-Risk Indicator for Hepatitis C Infection: Another Step Toward HCV Elimination.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Highly efficacious and tolerable treatments that cure hepatitis C viral (HCV) infection exist today, increasing the feasibility of disease elimination. However, large healthcare systems may not be fully prepared for supporting recommended actions due to knowledge gaps, inadequate infrastructure and uninformed policy direction. Additionally, the HCV cascade of care is complex, with many embedded barriers, and a significant number of patients do not progress through the cascade and are thus not cured. The aim of this retrospective cohort study was to evaluate a large healthcare system's HCV screening rates, linkage to care efficiency, and provider testing preferences. Patients born during 1945-1965, not previously HCV positive or tested from within the Electronic Health Record (EHR), were identified given that three-quarters of HCV-infected persons in the United States are from this Birth Cohort (BC). In building this HCV testing EHR prompt, non-Birth Cohort patients were excluded as HCV-specific risk factors identifying this population were not usually captured in searchable, structured data fields. Once completed, the BC prompt was released to primary care locations. From July 2015 through December 2016, 11.5% of eligible patients (n = 9,304/80,556) were HCV antibody tested (anti-HCV), 3.8% (353/9,304) anti-HCV positive, 98.1% (n = 311/317) HCV RNA tested, 59.8% (n = 186/311) HCV RNA positive, 86.6% (161/186) referred and 76.4% (n = 123/161) seen by a specialist, and 34.1% (n = 42/123) cured of their HCV. Results from the middle stages of the cascade in this large healthcare system are encouraging; however, entry into the cascade-HCV testing-was performed for only 11% of the birth cohort, and the endpoint-HCV cure-accounted for only 22% of all infected. Action is needed to align current practice with recommendations for HCV testing and treatment given that these are significant barriers toward elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.